📰 Simulations Plu News
Simulations Plu News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Simulations Plu. Real-time updates on events, politics, business and more.
May 22, 2024
Aurora Innovation (NASDAQ:AUR – Get Free Report) and Simulations Plus (NASDAQ:SLP – Get Free Report) are both computer and technology companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations. Institutional and Insider Ownership 44.7% of […]
April 27, 2024
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
April 6, 2024
Simulations Plus, Inc. ( NASDAQ:SLP ) investors will be delighted, with the company turning in some strong numbers with...
April 3, 2024
Strong Revenue Growth and Dividend Declaration in Q2 Fiscal 2024
October 25, 2023
Fiscal 2023 revenue increased 11% year-over-year to $59.6 million Provides Fiscal 2024 revenue guidance of $66 - $69 million and EPS guidance of $0.66 - $0.68 Simulations Plus to host its...
August 23, 2023
ECARX (NASDAQ:ECX – Get Free Report) and Simulations Plus (NASDAQ:SLP – Get Free Report) are both small-cap business services companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk. Analyst Ratings This is a summary of […]
July 3, 2023
Firms focus on drug-modeling software.
April 7, 2023
Simulations Plus, Inc. (NASDAQ:SLP – Get Rating) – Analysts at Oppenheimer boosted their FY2023 earnings per share estimates for shares of Simulations Plus in a research note issued to investors on Thursday, April 6th. Oppenheimer analyst F. Brisebois now forecasts that the technology company will post earnings per share of $0.66 for the year, up […]
April 7, 2023
Simulations Plus (NASDAQ:SLP – Get Rating)‘s stock had its “outperform” rating reaffirmed by investment analysts at Oppenheimer in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $65.00 price target on the technology company’s stock. Oppenheimer’s price objective would indicate a potential upside of 53.66% from the company’s […]
March 28, 2023
Drug discovery services partnership with Sino-American Cancer Foundation focuses on the development of actionable hits against the MTHFD2 target ... | March 28, 2023